148 related articles for article (PubMed ID: 28653394)
1. Ranolazine reduces repolarization heterogeneity in symptomatic patients with diabetes and non-flow-limiting coronary artery stenosis.
Evaristo E; Stocco FG; Shah NR; Cheezum MK; Hainer J; Foster C; Nearing BD; Di Carli M; Verrier RL
Ann Noninvasive Electrocardiol; 2018 Jan; 23(1):. PubMed ID: 28653394
[TBL] [Abstract][Full Text] [Related]
2. Marked exercise-induced T-wave heterogeneity in symptomatic diabetic patients with nonflow-limiting coronary artery stenosis.
Stocco FG; Evaristo E; Shah NR; Cheezum MK; Hainer J; Foster C; Nearing BD; Gervino E; Verrier RL
Ann Noninvasive Electrocardiol; 2018 Mar; 23(2):e12503. PubMed ID: 28949056
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.
Shah NR; Cheezum MK; Veeranna V; Horgan SJ; Taqueti VR; Murthy VL; Foster C; Hainer J; Daniels KM; Rivero J; Shah AM; Stone PH; Morrow DA; Steigner ML; Dorbala S; Blankstein R; Di Carli MF
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473401
[TBL] [Abstract][Full Text] [Related]
4. Exercise and pharmacologic stress-induced interlead T-wave heterogeneity analysis to detect clinically significant coronary artery stenosis.
Silva AC; de Antonio VZ; Sroubek J; Gervino E; Ho K; Medeiros SA; Silva FT; Pedreira GC; Stocco FG; Nearing BD; Verrier RL
Int J Cardiol; 2020 Jan; 298():32-38. PubMed ID: 31412992
[TBL] [Abstract][Full Text] [Related]
5. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
Tagliamonte E; Rigo F; Cirillo T; Astarita C; Quaranta G; Marinelli U; Caruso A; Romano C; Capuano N
Echocardiography; 2015 Mar; 32(3):516-21. PubMed ID: 25041234
[TBL] [Abstract][Full Text] [Related]
6. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
[TBL] [Abstract][Full Text] [Related]
7. Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate.
Golino M; Spera FR; Manfredonia L; De Vita A; Di Franco A; Lamendola P; Villano A; Melita V; Mencarelli E; Lanza GA; Crea F
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6545-6550. PubMed ID: 30338825
[TBL] [Abstract][Full Text] [Related]
8. Selective late sodium current blockade with GS-458967 markedly reduces ischemia-induced atrial and ventricular repolarization alternans and ECG heterogeneity.
Bonatti R; Silva AF; Batatinha JA; Sobrado LF; Machado AD; Varone BB; Nearing BD; Belardinelli L; Verrier RL
Heart Rhythm; 2014 Oct; 11(10):1827-35. PubMed ID: 24953379
[TBL] [Abstract][Full Text] [Related]
9. Interlead heterogeneity of R- and T-wave morphology in standard 12-lead ECGs predicts sustained ventricular tachycardia/fibrillation and arrhythmic death in patients with cardiomyopathy.
Tan AY; Nearing BD; Rosenberg M; Nezafat R; Josephson ME; Verrier RL
J Cardiovasc Electrophysiol; 2017 Nov; 28(11):1324-1333. PubMed ID: 28675579
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial.
Safdar B; D'Onofrio G; Dziura J; Russell RR; Johnson C; Sinusas AJ
Clin Ther; 2017 Jan; 39(1):55-63. PubMed ID: 28081848
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
[TBL] [Abstract][Full Text] [Related]
13. Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.
Verrier RL; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Zeng D; Belardinelli L
Heart Rhythm; 2013 Jan; 10(1):121-7. PubMed ID: 22985658
[TBL] [Abstract][Full Text] [Related]
14. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Venkataraman R; Belardinelli L; Blackburn B; Heo J; Iskandrian AE
JACC Cardiovasc Imaging; 2009 Nov; 2(11):1301-9. PubMed ID: 19909934
[TBL] [Abstract][Full Text] [Related]
15. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
16. Tracking cardiac electrical instability by computing interlead heterogeneity of T-wave morphology.
Nearing BD; Verrier RL
J Appl Physiol (1985); 2003 Dec; 95(6):2265-72. PubMed ID: 12897035
[TBL] [Abstract][Full Text] [Related]
17. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
18. Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Nieminen T; Scirica BM; Pegler JR; Tavares C; Pagotto VP; Kanas AF; Sobrado MF; Nearing BD; Umez-Eronini AA; Morrow DA; Belardinelli L; Verrier RL
Am J Cardiol; 2014 Jul; 114(1):17-23. PubMed ID: 24852915
[TBL] [Abstract][Full Text] [Related]
19. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
